NEW YORK, June 05, 2025 — MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a Japan-based holistic healthcare company (“MEDIROM” or the “Company”), announced today that on June 4, 2025, it received notification from Nasdaq confirming its compliance with the minimum bid price requirement outlined in Nasdaq Listing Rule 5550(a)(2).

MEDIROM had previously received a non-compliance notice from Nasdaq on February 27, 2025, due to its failure to maintain a minimum closing bid price of $1.00 per share. To regain compliance, the company’s American Depositary Shares (“ADSs”) needed to sustain a closing bid price of $1.00 or higher for a minimum of 10 consecutive business days. A grace period of 180 calendar days, expiring on August 26, 2025, was granted to achieve this.

Nasdaq verified on June 4, 2025, that the closing bid price of MEDIROM’s ADSs had been at or above $1.00 per share for the preceding 10 consecutive business days, spanning from May 20, 2025, to June 3, 2025. Consequently, Nasdaq has confirmed MEDIROM’s compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.

About MEDIROM Healthcare Technologies Inc.
MEDIROM, a holistic healthcare company, operates over 300 wellness salons across Japan, with Re.Ra.Ku® as its primary brand, offering healthcare services. In 2015, MEDIROM expanded into the health tech sector, introducing new healthcare programs through its on-demand training app, “Lav®,” which they developed. The company further diversified in 2020 by entering the device business, creating the “MOTHER Bracelet®” smart tracker. In 2023, MEDIROM launched REMONY, a remote monitoring system for business clients, securing orders from diverse sectors such as nursing care, transportation, construction, and manufacturing. MEDIROM aims to utilize its broad array of health-related products and services to gather and manage healthcare data from users and customers, establishing itself as a leader in healthcare big data in Japan. For more information, visit .

Forward-Looking Statements
This press release contains forward-looking statements regarding MEDIROM, which are not based on historical facts and are subject to safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These statements may include projections and estimates about MEDIROM’s future financial results, business strategies, market opportunities, and potential growth. These forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” and similar expressions that suggest uncertainty about future events. They are based on assumptions and current expectations of MEDIROM’s management and are subject to risks and uncertainties, including business, economic, competitive, and regulatory factors. Actual results may differ materially if these risks materialize or assumptions prove incorrect. MEDIROM is not obligated to update or revise these statements, even if new information becomes available.

Contact
Investor Relations Team

“`